Taiho VenturesIndex
投資· MANDATE
Letter № 04 · Q2 2026

Patient capital for early-stage therapeutics, backed by Taiho Pharmaceutical.

Taiho Ventures deploys $400M from Taiho Pharmaceutical’s balance sheet into preclinical-to-proof-of-concept programs in oncology, immunology, and urology.

We are typically brought into syndicates as a strategic participant. Our presence signals that a credible global pharmaceutical partner believes in the science, and may ultimately license, co-develop, or acquire the asset.

Fund size
$400M
Expanded 2024
Stage
Preclinical → PoC
Therapeutic areas
Oncology · Immunology · Urology
Models
Syndicate · Build-to-buy · Spin-out
Geography
North America · EU · Japan
Commitment
Single-team, single-balance-sheet
理念· APPROACH
§ 01

Three plans, one balance sheet.

We are a single team underwriting three flavors of risk. Each has its own diligence cadence, its own check size, and its own definition of success. We do not pretend they are the same.

  1. I.Research → Pre-IND

    Capital and scientific direction at the earliest stage.

    Seed and Series A participation in companies still validating biology. We expect to be wrong on a meaningful share of these. Conviction is built program-by-program, not platform-by-platform.

    Lead or co-lead · Board observer
  2. II.IND → Proof of concept

    Clinical-stage syndicates where we de-risk transitions.

    Series B and C participation in companies moving from preclinical confidence to first human readouts. We bring regulatory, manufacturing, and operational pattern-matching from a parent that has run the same gauntlet many times.

    Strategic participant · Cap-table signal
  3. III.Build-to-buy

    Company creation and spin-outs aligned with Taiho’s direction.

    Selectively, we form NewCos and back spin-outs structured for clean acquisition by Taiho Pharmaceutical at a defined milestone. Terms are visible to founders from day one. There are no surprises.

    Founder · Lead investor · Defined option

A bridge between breakthrough science and global commercialization — patient where venture is impatient, clinical where biotech is theoretical.

— TVL Investment Memo, 2026
実績· PORTFOLIO
§ 02

Selected positions.

A representative slice of active and exited positions. The full portfolio (32 companies, 6 active funds) is shared on request.

  1. 04 / 18

    Harpoon Therapeutics

    Syndicate position in a clinical-stage T-cell engager platform. Participated alongside a deep specialist syndicate; brought regulatory and CMC pattern-matching from the parent.

    Year
    2018
    Stage
    Series B
    Area
    T-cell engagers
    Model
    Syndicate
    Co-investors
    ARCH · NEA · New Leaf
  2. 07 / 19

    Cullinan Pearl

    NewCo carved out of Cullinan Oncology to advance a Taiho-originated EGFR exon 20 program. Acquired by Taiho Pharmaceutical in 2023 at a defined milestone.

    Year
    2019
    Stage
    Build-to-buy
    Area
    Pancreatic & gastric oncology
    Model
    Build-to-buy
    Co-investors
    Cullinan Oncology
  3. 11 / 20

    Arcus Biosciences

    Late-stage participation paired with a Taiho commercialization arrangement covering Japan and select Asian markets. Capital and a real channel, in one transaction.

    Year
    2020
    Stage
    Public follow-on
    Area
    Immuno-oncology
    Model
    Asia bridge
    Co-investors
    Gilead · Astellas
  4. 14 / 21

    Orna Therapeutics

    Platform-stage participation in a circular RNA company building a new modality. Underwritten as a multi-program option, not a single asset.

    Year
    2021
    Stage
    Series B
    Area
    Circular RNA
    Model
    Platform
    Co-investors
    MPM · RA Capital · F-Prime
強み· STRATEGIC VALUE
§ 03

What the parent brings — beyond the check.

Taiho Pharmaceutical has been developing oncology, immunology, and urology medicines for sixty years. Capital is the visible part of our participation; the rest is operational, regulatory, and commercial infrastructure that takes a global pharma decades to build.

For founders, this looks like real conversations with experienced regulatory leads, candid manufacturing diligence well before a Phase II readout, and — when the science is a fit — a defined path to Asian commercialization without a separate, distracting partnership cycle.